BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 16648508)

  • 1. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial.
    Bruera E; Valero V; Driver L; Shen L; Willey J; Zhang T; Palmer JL
    J Clin Oncol; 2006 May; 24(13):2073-8. PubMed ID: 16648508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial.
    Bruera E; El Osta B; Valero V; Driver LC; Pei BL; Shen L; Poulter VA; Palmer JL
    J Clin Oncol; 2007 Aug; 25(23):3475-81. PubMed ID: 17687152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report.
    Bruera E; Driver L; Barnes EA; Willey J; Shen L; Palmer JL; Escalante C
    J Clin Oncol; 2003 Dec; 21(23):4439-43. PubMed ID: 14645434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial.
    Kerr CW; Drake J; Milch RA; Brazeau DA; Skretny JA; Brazeau GA; Donnelly JP
    J Pain Symptom Manage; 2012 Jan; 43(1):68-77. PubMed ID: 22208450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.
    Butler JM; Case LD; Atkins J; Frizzell B; Sanders G; Griffin P; Lesser G; McMullen K; McQuellon R; Naughton M; Rapp S; Stieber V; Shaw EG
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1496-501. PubMed ID: 17869448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
    Lower EE; Fleishman S; Cooper A; Zeldis J; Faleck H; Yu Z; Manning D
    J Pain Symptom Manage; 2009 Nov; 38(5):650-62. PubMed ID: 19896571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
    Mendonça DA; Menezes K; Jog MS
    Mov Disord; 2007 Oct; 22(14):2070-6. PubMed ID: 17674415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does methylphenidate reduce the symptoms of chronic fatigue syndrome?
    Blockmans D; Persoons P; Van Houdenhove B; Bobbaers H
    Am J Med; 2006 Feb; 119(2):167.e23-30. PubMed ID: 16443425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J
    Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer.
    Auret KA; Schug SA; Bremner AP; Bulsara M
    J Pain Symptom Manage; 2009 Apr; 37(4):613-21. PubMed ID: 18790598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
    Bruera E; Yennurajalingam S; Palmer JL; Perez-Cruz PE; Frisbee-Hume S; Allo JA; Williams JL; Cohen MZ
    J Clin Oncol; 2013 Jul; 31(19):2421-7. PubMed ID: 23690414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methylphenidate in palliative care in cancer patient: a double-blind randomised trial versus placebo].
    Laval G; Paris A
    Bull Cancer; 2008 Feb; 95(2):241-6. PubMed ID: 18304907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
    Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot, randomized, modified, double-blind, placebo-controlled trial of acupuncture for cancer-related fatigue.
    Balk J; Day R; Rosenzweig M; Beriwal S
    J Soc Integr Oncol; 2009; 7(1):4-11. PubMed ID: 19476729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.